T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Urban Outfitters
URBN
$6.63B
| $27.5M | ﹤0.01% |
365,397
+131,539
| +56% | +$9.31M |
|
977
Olema Pharmaceuticals
OLMA
$913M
| $27.4M | ﹤0.01% |
1,096,035
+1,064,254
| +3,349% | +$18.9M |
|
978
Pricesmart
PSMT
$5.49B
| $27.3M | ﹤0.01% |
222,741
+1,246
| +0.6% | +$152K |
|
979
Trimble
TRMB
$13.4B
| $27.3M | ﹤0.01% |
348,576
-2,655
| -0.8% | -$212K |
|
980
Crocs
CROX
$6.26B
| $27.3M | ﹤0.01% |
318,632
+9,663
| +3% | +$808K |
|
981
A10 Networks
ATEN
$2B
| $27.2M | ﹤0.01% |
1,536,628
-36,437
| -2% | -$645K |
|
|
HOLX
982
DELISTED
Hologic
HOLX
| $27M | ﹤0.01% |
362,673
+9,196
| +3% | +$672K |
|
983
Planet Labs
PL
$8.82B
| $27M | ﹤0.01% |
1,369,657
-581,543
| -30% | -$8.34M |
|
984
Oric Pharmaceuticals
ORIC
$1.42B
| $27M | ﹤0.01% |
3,295,122
+423,795
| +15% | +$4.88M |
|
985
SoFi Technologies
SOFI
$23.8B
| $26.9M | ﹤0.01% |
1,026,149
+102,582
| +11% | +$2.86M |
|
986
Viavi Solutions
VIAV
$10.6B
| $26.8M | ﹤0.01% |
1,505,528
-444,131
| -23% | -$7.17M |
|
987
Rollins
ROL
$17.4B
| $26.8M | ﹤0.01% |
446,189
-126,218
| -22% | -$7.41M |
|
988
Wolfspeed
WOLF
$1.64B
| $26.8M | ﹤0.01% |
1,536,758
+5,988
| +0.4% | +$137K |
|
|
RAPP
989
Rapport Therapeutics
RAPP
$2.29B
| $26.7M | ﹤0.01% |
881,609
-220,782
| -20% | -$6.11M |
|
|
BCPC
990
Balchem Corp
BCPC
$5.65B
| $26.6M | ﹤0.01% |
173,403
-65,454
| -27% | -$9.99M |
|
|
MBX
991
MBX Biosciences
MBX
$3.23B
| $26.5M | ﹤0.01% |
840,506
-114,220
| -12% | -$2.77M |
|
992
Wheaton Precious Metals
WPM
$61.3B
| $26.5M | ﹤0.01% |
225,569
-71,692
| -24% | -$7.68M |
|
993
Principal Financial Group
PFG
$24.4B
| $26.5M | ﹤0.01% |
300,121
+5,192
| +2% | +$438K |
|
994
Pool Corp
POOL
$7.25B
| $26.4M | ﹤0.01% |
115,450
-79,756
| -41% | -$20.7M |
|
|
BCAX
995
Bicara Therapeutics
BCAX
$1.63B
| $26.2M | ﹤0.01% |
1,559,535
-195,876
| -11% | -$3.35M |
|
996
ePlus
PLUS
$2.32B
| $26.1M | ﹤0.01% |
298,050
+1,267
| +0.4% | +$105K |
|
997
Coca-Cola Europacific Partners
CCEP
$47.3B
| $26.1M | ﹤0.01% |
288,178
+27,411
| +11% | +$2.48M |
|
998
Pharvaris
PHVS
$2.55B
| $26.1M | ﹤0.01% |
941,605
+124,797
| +15% | +$3.01M |
|
999
Charter Communications
CHTR
$17.9B
| $26.1M | ﹤0.01% |
125,133
-383,551
| -75% | -$86.3M |
|
1000
Eagle Materials
EXP
$6.47B
| $26.1M | ﹤0.01% |
126,196
-134,962
| -52% | -$29.8M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.